Johnson & Johnson JNJ
271.22
0.54
0.20%
as of 25 Sep
- Market cap
- $652.8B
- P/E
- 31.4×
Follow JNJ
S&P 500 Member
Dividend Aristocrat
Cash Flow Champion (3y)
Revenue Champion (3y)
Insider Buys (last 12m)
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Johnson & Johnson (JNJ) Revenue
Johnson & Johnson's revenue for fiscal 2025 was $94.2B, up 6.05% from $88.8B in fiscal 2024. Over the twelve months to 30 June 2026 it was $97.9B. Over the past ten years it has ranged from $70.1B (fiscal 2015) to $94.2B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. Johnson & Johnson ranks 1st of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Annual
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $94.2B | 6.05% |
| FY2024 | $88.8B | 4.30% |
| FY2023 | $85.2B | 6.46% |
| FY2022 | $80.0B | 1.59% |
| FY2021 | $78.7B | (4.65%) |
| FY2020 | $82.6B | 0.64% |
| FY2019 | $82.1B | 0.59% |
| FY2018 | $81.6B | 6.71% |
| FY2017 | $76.5B | 6.34% |
| FY2016 | $71.9B | 2.59% |
Quarterly
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $25.3B | 5.19% |
| Mar 2026 | $24.1B | (2.04%) |
| Dec 2025 | $24.6B | 2.38% |
| Sep 2025 | $24.0B | 1.05% |
| 42 more quarters | Free account |
Against its own ten years
Low $70.1B
High $94.2B
Ten-year median
$81.6B
Current reading's percentile
100
Revenue against peers
| Company | Revenue |
|---|---|
| JNJ Johnson & Johnson | $97.9B |
| LLY Eli Lilly and Company compare | $79.7B |
| MRK Merck & Co., Inc. compare | $66.6B |
| ABBV AbbVie Inc. compare | $64.4B |
| PFE Pfizer Inc. compare | $63.7B |
| AZN AstraZeneca PLC compare | $61.4B |
| NVS Novartis AG compare | $56.7B |
| AMGN Amgen Inc. compare | $38.1B |
| GILD Gilead Sciences, Inc. compare | $30.5B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on JNJ
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement